INTRODUCTION
============

Nowadays, gastrointestinal-related cancers especially gastric cancer (GC) and colorectal cancer (CRC) are major causes of cancer-related death worldwide [@B7] ^,^ [@B22] ^,^ [@B23]. Globally, CRC and GC are the third and fourth leading cause most common cancers, making up 10% and 7% of cases all new cancer cases, respectively [@B23] ^,^ [@B27]. It is well-known that the development of CRC and GC can be induced by the interactions of multiple genetic and environmental factors in complex ways. However, the pathogenesis of CRC differs from that of GC in that it is affected by ethnic background, regional, life style, environmental factors and molecular pathogenesis[@B27]. Currently, several genes have been reported to be associated with CRC and GC, and the matrix metalloproteinases (MMPs) genes has received increasing attention^10,\ 29,31^.

MMPs are classified as a large family of zinc-containing proteases, which involved in normal physiological and pathological processes such as degradation and remolding of extracellular matrix, embryonic development, reproduction and cancer[@B6] ^,^ [@B13]. MMP-7, the smallest member of MMP family, is an endopeptidases with broad substrate specificity, which break down extracellular matrix (ECM) by degrading macromolecules including casein, type I, II, IV, and V gelatins, fibronectin, and proteoglycan[@B18]. In addition, MMP-7 is one of the main regulatory enzymes involved in apoptosis by releases the Fas ligand (FasL) from the membrane then induces apoptosis of neighboring cells, or decreases cancer-cell apoptosis[@B21]. Thus, MMP-7 promotes cell survival by resisting apoptosis through cleaving FasL. MMP7 is potentially involved in tumor metastasis and inflammatory processes[@B10] ^,^ [@B31].

MMP-7 gene (also known as matrilysin) is localized on chromosome 11q21-q22 and contains 13 exons[@B35]. The single nucleotide polymorphism (SNP) -181A\>G in promoter region of MMP-7 gene has been considered to be a candidate SNP for various conditions including gastrointestinal related malignancies[@B1] ^,^ [@B10] ^,^ [@B31]. There is clear evidence that MMP-7 gene up-regulation is significantly related to the promoter activity variation of the -181A\>G16. Molecular epidemiological studies have reported the association of MMP-7 -181A\>G polymorphism with CRC and GC risk, but the results remain conflicting rather than conclusive. Several studies previously have performed on the association of MMP-7 -181A\>G polymorphism with CRC and GC risk[@B10] ^,^ [@B31]. However, these studies had opposite observations and additional case-control studies with larger sample sizes have been published since then. Hence, the association of MMP-7 -181A\>G polymorphism remains unknown.

Therefore, we have performed a meta-analysis of all eligible studies to derive more precise estimation of the association of MMP-7 -181A\>G polymorphism with CRC and GC risk.

METHODS
=======

Literature search
-----------------

Following PRISMA guidance, we searched the electronic literature databases including PubMed, EMBASE, Elsevier, Science Direct, Wan Fang, Chinese National Knowledge Infrastructure (CNKI) and Chinese Biomedical Literature for all relevant articles published up to April 25, 2018. The search strategies were based on combinations of the following key words: (''matrix metalloproteinase-7'' OR ''MMP-7'' OR ''matrilysin'' OR uterine metalloproteinase OR ''pump-1 protease'' OR ''PUMP-1'') AND (''-181A\>G OR ''rs11568818'') AND (''colorectal cancer'' OR ''CRC'') AND (''gastric adenocarcinoma'' OR ''stomach cancer'' OR ''gastric cancer'' OR ''GC'') AND (''gene" or ''allele" or ''genotype" or ''mutation" or ''variant" or ''variation" or ''polymorphism"), without any restriction on language. Review articles were hand-searched to find additional eligible studies and only published studies with full-text articles were included. We excluded studies that were not full-length publications articles or letters in peer-reviewed English journals. When the same patient population was included in different articles, the one with the largest population of participants or the most recent one was selected.

Inclusion and exclusion criteria
--------------------------------

Inclusion criteria was defined as follows: 1) published studies and contained original data; 2) case-control studies; 3) evaluating the association of MMP-7 -181A\>G polymorphism with CRC and GC risk; and 4) sufficient published data available to estimate an odds ratio (OR) with 95% confidence interval (CI). Major reasons for exclusion of studies were as follows: 1) only case population, family based or linkage studies; 2) studies that could not offer the number of cases and controls or other essential data; 3) reviews, abstracts, letters to editor, case reports or animal studies; 4) duplicate of previous publication or studies with overlapping patient populations; and 5) studies without histologically confirmed of CRC and GC. For more than two studies with overlapping data, the study with the most subjects or newest published data was selected.

Data extraction
---------------

Data were carefully extracted from all eligible publications by two of the authors independently. If the study provided stratum information, the data coming from similar stratum were added up to make full use of the data. Disagreements between the two authors were resolved by discussing the results with a third one. For each study, the following variables were collected: first author's name, year of publication, country, ethnicity of participants, number of cases and controls, genotyping methods, and allele numbers and genotype distributions in cases and controls, minor allele frequencies (MAFs) in control subjects, and the results of Hardy-Weinberg equilibrium (HWE) test. Different ethnicities were categorized as Asian, Caucasian and Latinos (mixed). Study designs were stratified to population-based studies and hospital-based studies.

Statistical analysis
--------------------

The strength of the association of MMP-7 -181A\>G polymorphism with CRC and GC risk was measured using odds ratios (ORs) with 95% confidence intervals (CIs). The statistical significance of the pooled OR was assessed with the Z-test and p\<0.05 was considered significant. The pooled ORs were performed under five genetic models, i.e., allele (G vs. A), heterozygote (GA vs. AA), homozygote (GG vs. AA), dominant (GG+GA vs. AA) and recessive (GG vs. GA+AA). The between-study heterogeneity was evaluated by a chi-square-based Q test, which p value for the Q-test less than 0.10 indicates existing heterogeneity among studies. In addition, the I^2^ statistics was used to quantify the proportion of the total variation across studies due to heterogeneity. A high value of I2 indicated a higher probability of the existence of heterogeneity (I^2^=0% to 25%, no heterogeneity; I^2^=25% to 50%, moderate heterogeneity; I^2^=50% to 75%, large heterogeneity; and I^2^=75% to 100%, extreme heterogeneity). A random-effects (DerSimonian- Laird method) or fixed-effects (Mantel-Haenszel method) model was used to calculate pooled effect estimates in the presence or absence of heterogeneity. HWE of genotype distribution in the controls of included studies was conducted using by Pearson's x [@B2] test, in which p-value less than 0.05 was considered significantly deviating from HWE. Subgroup analyses were performed by ethnicity, genotyping method, HWE status, source of controls and cancer type (CRC and GC). In addition, to consider the possible sources of heterogeneity, the studies we stratified. To validate the reliability of the results, sensitivity analysis was performed though omitting one case-control study each time, as well as limiting this meta-analysis to studies which were conformed to HWE. Funnel plots and Egger's linear regression test were used to diagnose potential publication bias (p\<0.05). All analyses were performed with the comprehensive meta-analysis (CMA) 2.0 software (Biostat, USA). Two-sided p-values\<0.05 were considered statistically significant.

RESULTS
=======

Extraction process and study characteristics
--------------------------------------------

The flow diagram of literature search was given in [Figure 1](#f1){ref-type="fig"}. The initial search of databases yielded 103 relevant publications based on our literature search strategy, and an additional one study was identified through hand searching. However, 36 of them were ruled out because of duplicate results obtained from multiple databases, 68 articles remained. In addition, after the titles and abstracts of the 68 articles were reviewed, 49 full-text irrelevant studies were excluded. Finally, 19 eligible case-control studies with 3,714 cases and 4,712 controls were included in this meta-analysis. The characteristics of studies included in the current meta-analysis are shown in [Table 1](#t1){ref-type="table"}. Among these studies, eleven studies with 2,169 CRC cases and 2,346 controls were on CRC[@B2] ^-^ [@B4] ^,^ [@B8] ^,^ [@B16] ^,^ [@B19] ^,^ [@B20] ^,^ [@B24] ^,^ [@B28] ^,^ [@B33], and eight studies with 1,545 GC cases and 2,366 controls were on GC[@B5] ^,^ [@B11] ^,^ [@B12] ^,^ [@B14] ^,^ [@B15] ^,^ [@B17] ^,^ [@B26] ^,^ [@B34]. By ethnics, there were 13 studies of Asians (countries: Korea, Japan, China, Iran, Kashmir, Taiwan, and India), four studies of Caucasians (countries: Italy, France, Poland and Netherland), and two studies of Latinos (countries: Brazil and Mexico). According to the control source, ten studies were hospital-based, eight studies were population-based and one study was not clear. The studies used four different genotyping methods including direct sequencing, TaqMan, polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis and tetra-primer amplification refractory mutation system-polymerase chain (ARMS-PCR). All of the studies indicated that the distribution of genotypes in the controls was consistent with HWE except for two studies ([Table 1](#t1){ref-type="table"}).

FIGURE 1The study selection and inclusion process.

TABLE 1Main characteristics of all studies included in the meta-analysisFirst AuthorCountry (Ethnicity)Genotyping TechniqueSOCCase/ControlCasesControlsMAFsHWEGenotypeAlleleGenotypeAlleleAAAGGGAGAAAGGGAGColorectal CancerGhilardi 2003Italy (Caucasian)SequencingPB58/1111528155858366114133890.4000.129Lievre 2006France (Caucasian)TaqManPB596/56519127213165853418725911910834970.4390.097Woo 2007Korea (Asian)PCR-RFLPPB185/30416322034822265390565390.0640.232Ohtani 2009Japan (Asian)PCR-RFLPHB119/6711090229955120122120.0890.420de Lima 2009Brazil (Latinos)PCR-RFLPHB108/11336561612888415715139870.3840.487Fang 2010China (Asian)PCR-RFLPPB252/2372230047430218190455190.0400.520Dziki 2011Poland (Caucasian)PCR-RFLPHB184/2059993521711976694452161940.4730.294Moreno-Ortiz 2014México (Latinos)PCR-RFLPHB102/1214651514361495418152900.3710.622Motoval-Bashi 2015Iran (Asian)ARMS-PCRNS61/77113119536964031521020.7080.156Banday 2016Kashmir (Asian)PCR-RFLPHB142/1844382131761086184392061620.4400.317Yueh 2018Taiwan (Asian)PCR-RFLPHB362/36231838667450311438665590.081=0.001Gastric CancerZhang 2005China (Asian)PCR-RFLPPB201/35016734036834316331662350.0500.888Kubben 2006Nederland (Caucasian)PCR-RFLPPB79/169343781055346106171981400.414=0.001Sugimoto 2008Japan (Asian)PCR-RFLPHB160/43413327029327393401826420.0480.986Li 2008China (Asian)PCR-RFLPPB338/38028056261660342371721390.0510.999Kim 2011Korea (Asian)PCR-RFLPHB153/32612824128026280451605470.0720.565Malik 2011India (Asian)PCR-RFLPPB108/195293940981196392402181720.4410.547Fang 2013China (Asian)PCR-RFLPHB246/25223610048210222300474300.0590.315Kesh 2015India (Asian)PCR-RFLPHB260/26010710845322198118116263521680.3230.746[^2]

Quantitative synthesis
----------------------

### Overall study

[Table 2](#t2){ref-type="table"} listed the main results of the meta-analysis of MMP-7 -181A\>G polymorphism with CRC and GC risk. We pooled all the 19 case-control studies together to assess the overall association of MMP-7 -181A\>G polymorphism with CRC and GC risk. Overall, no significant main effects on CRC and GC susceptibility were observed in the overall population under all the five genetic models, i.e., allele (G vs. A: OR=1.049, 95% CI 0.889-1.239, p=0.570, [Figure 2](#f2){ref-type="fig"}A), heterozygote (GA vs. AA: OR=1.083, 95% CI 0.813-1.443, p=0.586), homozygote (GG vs. AA: OR=0.982, 95% CI 0.701-1.375, p=0.915), dominant (GG+GA vs. AA: OR=1.061, 95% CI 0.869-1.296, p=559) and recessive (GG vs. GA+AA: OR=1.084, 95% CI 0.786-1.495, p=0.622).

TABLE 2Meta-analysis for the association of MMP-7 -181A\>G polymorphism with CRC and GC riskSubgroupGenetic modelType of modelHeterogeneityOdds ratio (OR)Publication biasI2 (%)PHOR95% CIZORPORPBeggsPEggersOverall (n=19)G vs. ARandom70.90=0.0011.0490.889-1.2390.5680.5700.2930.483 GA vs. AARandom82.36=0.0011.0830.813-1.4430.5450.5860.2930.906 GG vs. AARandom54.650.0060.9820.701-1.375-0.1070.9150.7660.611 GG+GA vs. AARandom65.43=0.0011.0610.869-1.2960.5850.5590.0680.223 GG vs. GA+AARandom60.480.0011.0840.786-1.4950.4940.6220.6920.651Colorectal cancer (n=11)G vs. ARandom58.320.0080.9470.791-1.133-0.5930.5530.2750.345 GA vs. AARandom85.27=0.0011.1010.721-1.6820.4440.6570.8760.779 GG vs. AARandom58.510.0180.7910.529-1.183-1.1420.2530.5360.330 GG+GA vs. AAFixed42.240.0681.0320.894-1.1920.4310.6670.5330.355 GG vs. GA+AARandom68.090.0030.8780.589-1.309-0.6390.5230.9010.401Gastric cancer (n=8)G vs. ARandom76.10=0.0011.2150.897-1.6451.2560.2090.9010.459 GA vs. AARandom79.18=0.0011.0630.711-1.5900.3000.7640.0350.233 GG vs. AAFixed0.000.4851.6721.161-2.4092.7630.0060.2290.499 GG+GA vs. AARandom78.48=0.0011.1320.771-1.6600.6320.5270.1070.222 GG vs. GA+AAFixed0.000.7891.8351.319-2.5543.604=0.0010.3670.310Colorectal CancerAsian (n=6)G vs. AFixed47.830.0880.7980.661-0.964-2.3370.0190.7070.796 GA vs. AARandom91.80=0.0011.2160.486-3.0400.4160.6760.7070.959 GG vs. AAFixed0.000.6120.4900.286-0.838-2.6060.0091.0000.995 GG+GA vs. AAFixed46.520.0960.8960.708-1.134-0.9150.3600.7070.189 GG vs. GA+AAFixed0.000.3970.5300.340-0.826-2.8080.0051.0000.587Caucasian (n=3)G vs. AFixed40.680.1851.1230.981-1.2851.6760.0940.2960.126 GA vs. AAFixed38.970.1940.9230.744-1.143-0.7360.4611.0000.844 GG vs. AAFixed59.280.0861.0540.812-1.3660.3930.6941.0000.643 GG+GA vs. AAFixed53.130.1181.1800.960-1.4511.5690.1171.0000.460 GG vs. GA+AAFixed51.030.1301.2100.962-1.5221.6280.1040.2960.001Latinos (n=2)G vs. AFixed55.620.1330.8970.681-1.181-0.7730.440NANA GA vs. AAFixed0.000.7951.0590.709-1.5810.2780.781NANA GG vs. AARandom75.980.0410.6250.157-2.488-0.6670.505NANA GG+GA vs. AAFixed0.000.4760.9470.645-1.392-0.2760.783NANA GG vs. GA+AARandom76.580.0390.6060.162-2.267-0.7430.457NANAGastric Cancer Asian (n=7)G vs. ARandom69.580.0031.3310.994-1.7821.9180.0551.0000.451 GA vs. AARandom74.590.0011.1970.815-1.7580.9170.3590.2290.368 GG vs. AAFixed0.000.9761.9761.331-2.9343.3800.0010.2590.298 GG+GA vs. AARandom71.980.0021.2810.898-1.8261.3670.1720.3670.341 GG vs. GA+AAFixed0.000.9532.0221.416-2.8863.877=0.0010.2590.240[^3]

FIGURE 2Forest plot for the association of MMP-7 -181A\>G polymorphism with CRC and GC risk: A) the allele model (G vs. A) in overall estimations; B) the homozygote model (GG vs. AA) in GC studies

Colorectal cancer
-----------------

[Table 2](#t2){ref-type="table"} also listed the main results of the meta-analysis of MMP-7 -181A\>G polymorphism with CRC risk. When all the 11 eligible studies were pooled into the meta-analysis of MMP-7 -181A\>G polymorphism, we have not found evidence of a significant MMP-7 -181A\>G polymorphism with CRC risk under all the five genetic models. In the subgroup analysis by ethnicity, significantly increased risk of CRC was observed in Asians under three genetic models, i.e., allele (G vs. A: OR=0.798, 95% CI 0.661-0.964, p=0.019, [Figure 2](#f2){ref-type="fig"}A), homozygote (GG vs. AA: OR=0.490, 95% CI 00.286-0.838, p=0.009) and recessive model (GG vs. GA+AA: OR=0.530, 95% CI 0.340-0.826, p=0.005), but not in Caucasians and Latinos populations ([Table 2](#t2){ref-type="table"}).

We also performed subgroup analyses based on the source of control and genotyping method, when it was available ([Table 3](#t3){ref-type="table"}). The hospital-based subgroup analysis revealed that the presence of the MMP-7 -181A\>G polymorphism was related to a higher risk of CRC under the homozygote model (GG vs. AA: OR=0.671, 95% CI 0.484-0.951, p=0.023). In the PCR-RFLP group, significantly increased association between MMP-7 -181A\>G polymorphism and CRC risk was found under the homozygote model (GG vs. AA: OR=0.680, 95% CI 0.486-0.950, p=0.024, [Table 3](#t3){ref-type="table"}).

TABLE 3Meta-analysis for the association of MMP-7 -181A\>G polymorphism with CRC and GC riskSubgroupGenetic modelType of modelHeterogeneityOdds ratio (OR)Publication biasI2 (%)PHOR95% CIZORPORPBeggsPEggersColorectal Cancer PB (n=4)G vs. AFixed21.990.2791.0890.943-1.2571.1590.2460.7340.390 GA vs. AARandom94.02=0.0011.9610.660-5.8291.2110.2260.3080.456 GG vs. AAFixed65.720.0881.1780.871-1.5951.0630.288NANA GG+GA vs. AAFixed0.000.5181.0890.890-1.3330.8290.4070.3080.414 GG vs. GA+AAFixed71.990.0591.1530.885-1.5031.0540.292NANAHB (n=6)G vs. ARandom59.110.0320.8840.688-1.135-0.9690.3330.0600.118 GA vs. AAFixed45.410.1030.8920.720-1.106-1.0390.2991.0000.585 GG vs. AAFixed25.380.2500.6710.484-0.951-2.2600.0230.8060.583 GG+GA vs. AARandom56.090.0440.9710.701-1.347-0.1740.8620.7070.192 GG vs. GA+AARandom73.180.0050.7020.367-1.341-1.0720.2840.8060.258PCR-RFLP (n=8)G vs. ARandom52.420.0400.9340.751-1.160-0.6200.5360.3860.396 GA vs. AARandom89.23=0.0011.2120.665-2.2100.6270.5310.3860.423 GG vs. AAFixed25.410.2520.6800.486-0.950-2.2610.0240.8060.583 GG+GA vs. AAFixed47.450.0651.0220.785-1.3310.1650.8690.9010.260 GG vs. GA+AARandom73.180.0050.7020.367-1.341-1.0720.2840.8060.258Gastric Cancer PB (n=4)G vs. ARandom77.980.0031.3600.884-2.0931.4010.1610.7340.873 GA vs. AARandom83.08=0.0011.1380.601-2.1550.3970.6920.0890.192 GG vs. AAFixed39.160.1771.5040.911-2.4841.5950.1110.7340.678 GG+GA vs. AARandom81.360.0011.2440.693-2.2330.7330.4640.0890.239 GG vs. GA+AAFixed0.000.4001.8191.173-2.8192.6730.0080.7340.490HB (n=4)G vs. ARandom80.170.0021.0480.622-1.7660.1780.8590.7340.478 GA vs. AARandom80.400.0020.9850.545-1.781-0.0490.9610.7340.576 GG vs. AAFixed0.000.9181.8841.107-3.2042.3360.0200.2960.644 GG+GA vs. AARandom81.010.0011.0160.564-1.8310.0540.9570.3080.475 GG vs. GA+AAFixed0.000.9011.8581.124-3.0692.4170.0160.2960.621[^4]

Gastric cancer
--------------

[Table 2](#t2){ref-type="table"} also listed the main results of the meta-analysis of MMP-7 -181A\>G polymorphism with GC risk. There was a significant association between MMP-7 -181A\>G polymorphism and GC risk under two genetic models, i.e., homozygote (GG vs. AA: OR=1.672, 95% CI 1.161-2.409, p=0.006, [Fig 2](#f2){ref-type="fig"}B) and recessive (GG vs. GA+AA: OR=1.835, 95% CI 1.319-2.554, p=0.001). Similarly, when stratified by ethnicity, a significant association between MMP-7 -181A\>G polymorphism and increased risk of GC was detected among Asians under the homozygote model (GG vs. AA: OR=1.975, 95% CI 1.331-2.934, p=0.006) and the recessive model (GG vs. GA+AA: OR=2.022, 95% CI 1.416-2.886, p=0.001).

The studies were further stratified on the basis of source of controls ([Table 3](#t3){ref-type="table"}). When stratifying by source of control, a significant association between MMP-7 -181A\>G polymorphism and increased risk of GC was detected in population-based studies under the recessive model (GG vs. GA+AA: OR=1.819, 95% CI 1.173-2.819, p=0.008), and in hospital-based studies under two genetic models, i.e., homozygote (GG vs. AA: OR=1.884, 95% CI 1.107-3.204, p=0.020) and recessive (GG vs. GA+AA: OR=1.858, 95% CI 1.124-3.069, p=0.016).

Heterogeneity analysis
----------------------

Heterogeneity was detected among studies under all the five genetic models, i.e., allele (G vs. A: I2=70.90%, PH=0.001), heterozygote (GA vs. AA: I2=82.36%, PH=0.001), homozygote (GG vs. AA: I2=54.65%, PH=0.006), dominant (GG+GA vs. AA: I2=65.43%, PH=0.001) and recessive (GG vs. GA+AA: I2=65.4%, PH=0.001). Thus, to explore the potential sources of heterogeneity across studies, we assessed the pooled ORs via stratification by cancer type, ethnicity, genotyping method, HWE status and source of controls. The results showed that the heterogeneity effectively removed by subgroup analyses based on ethnicity among studies on CRC. Therefore, we found that genotyping method, HWE status and source of controls did not contribute to substantial heterogeneity among the meta-analysis.

Sensitivity analysis
--------------------

To evaluate the effect of individual study on the pooled ORs and stability of the meta-analysis results, we excluded one study at a time. However, the omission of any single study made no significant difference, suggesting that the results of this meta-analysis were stable. Moreover, sensitivity analysis was performed after excluding HWE-violating studies, and the corresponding pooled ORs were not qualitatively altered (data not shown).

Publication bias
----------------

Both Begg's funnel plot and Egger's test were performed to assess the publication bias of literature. Begg's funnel plots did not reveal any evidence of obvious asymmetry under all five genetic models in the overall meta-analysis. For example, the shape of the funnel plot did not indicate any evidence of obvious asymmetry under the allele model ([Figure 3](#f3){ref-type="fig"}), and the Egger's test suggested the absence of publication bias (PBeggs=0.293 and PEggers=0.483). However, the results of Egger's regression test showed evidence of publication bias among Caucasian's studies on CRC under the recessive model (GG vs. GA+AA: PBegg's=0.296, PEggers=0.001).

FIGURE 3Begg's funnel plots of the MMP-7 -181A\>G polymorphism with CRC and GC risk for publication bias test under the allele model (G vs. A): each point represents a separate study for the indicated association

Minor allele frequencies (MAFs)
-------------------------------

The minor allele frequencies (MAFs) of the MMP-7 -181A\>G polymorphism are shown in [Table 2](#t2){ref-type="table"}. The allele and genotype distributions of MMP-7 -181A\>G polymorphism exhibited ethnic variations. The MMP-7 -181A\>G polymorphism MAF in overall populations, Asians, Caucasians and Latinos were 37.4% (4.0%-70.8%), 37.4% (4.0%-70.8%), 43.65% (40.0%-47.30%), and 37.75% (37.1%-38.4%), respectively.

DISCUSSION
==========

MMP-7 gene is implicated in cancer susceptibility and metastasis in a variety of gastrointestinal-related cancers ^19,\ 11^. In the recent decade, several molecular epidemiological studies have been performed to assess the association of MMP-7 -181A\>G polymorphism with CRC and GC risk. However, the results were conflicting. Thus, we conducted a comprehensive meta-analysis involving published data, to assess the strength of association of MMP-7 -181A\>G polymorphism CRC and GC risk. In current meta-analysis, a total of 19 case-control studies including 3,714 cases and 4,712 controls were recruited. The subgroup analysis by cancer type, showed that there was significant association between the MMP-7 -181A\>G polymorphism and increased risk of GC in overall estimations, but not with CRC. In a stratified analysis by ethnicity, our results indicated that MMP-7 -181A\>G polymorphism was associated with a significantly increased risk of CRC and GC in Asians. Moreover, stratified analysis according to source of controls and genotyping method revealed a significantly increased risk of CRC and GC in participants with the MP-7 -181A\>G polymorphism in those studies involving PCR-RFLP, population-based and hospital-based ([Table 3](#t3){ref-type="table"}).

Our results were consistent with the previous meta-analyses on MMP-7 -181A\>G polymorphism and GC risk. Thus, MMP-7 -181A\>G polymorphism might serve as a susceptibility marker to GC risk. However, our results are inconsistent with the previous meta-analyses on MMP-7 -181A\>G polymorphism and CRC risk. In 2013, two meta-analyses by Ke et al and Yang et al were conducted to examine the association between MMP-7 -181A\>G polymorphism and CRC risk [@B10] ^,^ [@B31]. Ke et al in meta-analysis of seven case-control have found a significant association between MMP-7 -181A\>G polymorphism and CRC under the homozygote model (GG vs. AA, OR=1.13, 95% CI=1.01-1.26) [@B10]. Similarly, Yang et al in a meta-analysis of seven studies with 1,502 CRC cases and 1,602 controls found significant association between MMP-7 -181A\>G polymorphism and CRC under the homozygote model (OR=1.31, 95% CI 1.02-1.69) [@B31]. However, their findings about MMP-7 -181A\>G polymorphism and CRC risk essentially remains an open field, as the number of studies is considerably smaller than that needed to yield a robust conclusion. In addition, the previous meta-analyses did not perform stratified analysis by ethnicity to identify possible association of MMP-7 -181A\>G polymorphism with CRC among different ethnic groups.

Between-studies heterogeneity plays an important role when performing a meta-analysis [@B32]. Heterogeneity could result from study design, genotyping error, selection bias, population stratification, sample size, allelic heterogeneity, or chance [@B9] ^,^ [@B25]. Therefore, finding the source of heterogeneity is very important for the final result of meta-analysis. Through performing sub group analysis, we found that the heterogeneity could not be explained by genotyping method, HWE status and source of controls in this meta-analysis. However, the results showed that the heterogeneity effectively removed by subgroup analysis based on ethnicity among studies on CRC, indicating that studies among Asian populations regarding CRC might be a source of the heterogeneity in our meta-analysis.

This meta-analysis had three main strengths. First, this is the biggest and most recent meta-analysis of the association of MMP-7 -181A\>G polymorphism with CRC and GC risk, and it was more powerful than previous single case-control studies. Second, this is the first meta-analysis by subgroup analysis showed that the MMP-7 -181A\>G polymorphism was associated with CRC risk in Asians. Third, a comprehensive searching strategy from several electronic databases with manual search made the eligible studies included as much as possible.

Despite the clear strengths of this meta-analysis, limitations of our meta-analysis should be noted. First, although all the eligible studies were included to this meta-analysis, the sample size of the included studies was not large enough, which could increase the likelihood of type I and type II errors. Therefore, there was a lack of statistical power to better evaluate the association of MMP-7 -181A\>G polymorphism with CRC and GC risk. Second, most of included studies in the present meta-analysis mainly provided data in Asians. In addition, the sample size was relatively small for stratified analyses by ethnicity and might not have provided sufficient power to estimate the association of MMP-7 -181A\>G polymorphism among different ethnic groups. Third, although the funnel plot and Egger's test did not show evidence of publication bias in overall estimations, the influence of bias in the present analysis could not be completely excluded. For example, the negative findings are usually difficult to get published, or in this meta-analysis we have included only studies published in English, which produced selection bias at the start of our study. Fourth, the present meta-analysis was based primarily on unadjusted effect estimates, because most studies did not provide the adjusted OR and 95%CI controlling for potential confounding factors, thus the effect estimates were relatively imprecise. If individual data were available, adjusted ORs could be obtained to give a more precise analysis. Finally, it is well known that CRC and GC are multifactor conditions; however, the effects of gene-gene and gene-environment interactions were not addressed in the current meta-analysis.

CONCLUSION
==========

This meta-analysis indicated that the MMP-7 -181A\>G polymorphism might be a risk factor for susceptibility to GC in overall estimations and in Asians. However, our results clearly showed that the MMP-7 -181A\>G polymorphism significantly increased the risk of CRC only in Asians. Considering the limited sample size and ethnicities, well-designed studies taking into consideration of gene-gene and gene-environment interactions should be performed to confirm our results.
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